Recombinant FVIIIFc Versus BAY 94-9027 For Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison

Version 3 2021-01-04, 18:15

Version 2 2020-12-23, 16:09

Version 1 2020-12-23, 11:40

media

posted on 2021-01-04, 18:15 authored by Zalmai Hakimi, Elena Santagostino, Maarten J. Postma, Jameel Nazir

Article full text

The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

History

Usage metrics

Keywords

Annualised bleeding rate BAY 94-9027 Damactocog alfa pegol Efmoroctocog alfa Factor VIII-Fc fusion protein Haematology Haemophilia A; rFVIII Treatment outcome

Licence

CC BY-NC 4.0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM